On October 8, 2026, Beyond Air, Inc. (NASDAQ: XAIR) issued a press release announcing preliminary, unaudited revenue for the quarter ended September 30, 2026. The company reported revenue of approximately $2.3 million for the period. This figure represents the highest quarterly revenue reported by the company to date.
The preliminary revenue reflects a sequential increase of approximately 30% compared to the quarter ended June 30, 2026. Additionally, it represents a 27% increase over the same period in the prior year. The company attributes this growth to the continued adoption of its first-generation LungFit PH system and the execution of its enhanced commercial strategy.
Beyond Air noted that its second-generation LungFit PH system remains under review by the U.S. Food and Drug Administration (FDA). The company reaffirmed its previously issued revenue guidance for calendar years 2026 and 2027. For 2026, the company expects revenue of $8 million, excluding revenue from the second-generation system. For 2027, the company projects revenue of $16 million to $18 million, which includes anticipated revenue from the second-generation system pending FDA approval.
The preliminary revenue figures are unaudited and based on management’s estimates as of October 8, 2026. The company stated that the figures remain subject to the completion of financial closing procedures and review by its independent registered public accounting firm. Actual results may differ materially from these preliminary estimates. Beyond Air expects to report its complete financial results for the quarter ended September 30, 2026 in November 2026.
